Cargando…

Clinical pharmacokinetics and drug exposure-toxicity correlation study of docetaxel based chemotherapy in Chinese head and neck cancer patients

BACKGROUND: Area under time-concentration curve (AUC) of docetaxel is related with its toxicity and efficacy. The aim of this study is to investigate the target range of docetaxel AUC in Chinese head and neck cancer (HNC) patients. METHODS: Eligible HNC patients were enrolled and received at least 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Yuxiang, Lin, Qingguang, Yang, Yunpeng, Liang, Weiting, Salamone, S. J., Li, Yunying, Lin, Yuehao, Zhao, Hongyun, Zhao, Yuanyuan, Fang, Wenfeng, Huang, Yan, Zhang, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154422/ https://www.ncbi.nlm.nih.gov/pubmed/32309383 http://dx.doi.org/10.21037/atm.2020.01.76

Ejemplares similares

Therapeutic drug monitoring of docetaxel by pharmacokinetics and pharmacogenetics: A randomized clinical trial of AUC‐guided dosing in nonsmall cell lung cancer
por: Ma, Yuxiang, et al.
Publicado: (2021)

Docetaxel in the treatment of squamous cell carcinoma of the head and neck
por: Rapidis, Alexander, et al.
Publicado: (2008)

Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer
por: Sheng, Jin, et al.
Publicado: (2016)

Erratum: Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer
por: Sheng, Jin, et al.
Publicado: (2016)

Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic Chemotherapy
por: Hu, Zhihuang, et al.
Publicado: (2016)

Changes in ischemia-modified albumin in myocardial toxicity induced by anthracycline and docetaxel chemotherapy
por: Luan, Xiao-Dong, et al.
Publicado: (2017)

Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma
por: Ma, Yuxiang, et al.
Publicado: (2021)

Phase I study of camrelizumab in patients with advanced solid tumors
por: Ma, Yuxiang, et al.
Publicado: (2023)

Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis
por: Zhou, Yixin, et al.
Publicado: (2018)

Predictive Biomarkers for Response and Toxicity of Induction Chemotherapy in Head and Neck Cancers
por: Boguszewicz, Łukasz
Publicado: (2022)

Docetaxel population pharmacokinetic modelling and simulation in Chinese cancer patients
por: Wei, Jian, et al.
Publicado: (2022)

The Acute Toxicities and Efficacy of Concurrent Chemotherapy With Docetaxel Plus Cisplatin, or Docetaxel, or Cisplatin and Helical Tomotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Single-Center Phase II Trial
por: Luo, Yanrong, et al.
Publicado: (2022)

Toxic optic neuropathy in the setting of docetaxel chemotherapy: a case report
por: Moloney, Thomas P, et al.
Publicado: (2014)

Generic docetaxel chemotherapy induced skin toxicities in breast cancer patient
por: Elalami, Iliass, et al.
Publicado: (2016)

Nab-paclitaxel-based compared to docetaxel-based induction chemotherapy regimens for locally advanced squamous cell carcinoma of the head and neck
por: Schell, Amy, et al.
Publicado: (2015)

Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose
por: Kenmotsu, Hirotsugu, et al.
Publicado: (2015)

Pharmacokinetics and Toxicities of Oral Docetaxel Formulations Co-Administered with Ritonavir in Phase I Trials
por: Vermunt, Marit, et al.
Publicado: (2021)

Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck
por: Posner, M R, et al.
Publicado: (2003)

Ribophorin II Overexpression Is Associated with Poor Response to Induction Chemotherapy with Docetaxel, Cisplatin, and Fluorouracil in P16-Negative Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Chen, Wei-Shan, et al.
Publicado: (2021)

Efficacy and safety of nanosomal docetaxel lipid suspension-based chemotherapy in squamous cell carcinoma of the head and neck: A multicenter retrospective study
por: Kumar Das Majumdar, Saroj, et al.
Publicado: (2020)

A Phase I/II Open‐Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors
por: Ma, Yuxiang, et al.
Publicado: (2019)

EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients
por: Zheng, Qiufan, et al.
Publicado: (2020)

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
por: Zheng, Qiufan, et al.
Publicado: (2020)

Predictive factors of toxicity of TPF induction chemotherapy for locally advanced head and neck cancers
por: Bernadach, Maureen, et al.
Publicado: (2021)

Targeting mTOR-CCL20 Signaling May Improve Response to Docetaxel in Head and Neck Squamous Cell Carcinoma
por: Chou, Ming-Huei, et al.
Publicado: (2021)

Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil
por: Su, Yan-Ye, et al.
Publicado: (2016)

Anti‐epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first‐line treatment for recurrent or metastatic nasopharyngeal carcinoma
por: Chen, Chen, et al.
Publicado: (2020)

Multicenter phase II study of weekly docetaxel, cisplatin, and S-1 (TPS) induction chemotherapy for locally advanced squamous cell cancer of the head and neck
por: Bae, Woo Kyun, et al.
Publicado: (2013)

The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis
por: Kim, Ryul, et al.
Publicado: (2016)

Ratio of C-Reactive Protein/Albumin is An Inflammatory Prognostic Score for Predicting Overall Survival of Patients with Small-cell Lung Cancer
por: Zhou, Ting, et al.
Publicado: (2015)

The Effectiveness of RECIST on Survival in Patients with NSCLC Receiving Chemotherapy with or without Target Agents as First-Line Treatment
por: Zhou, Ting, et al.
Publicado: (2015)

Adjuvant chemotherapy in head and neck cancer.
por: Stell, P. M., et al.
Publicado: (1990)

Head and neck cancer: metronomic chemotherapy
por: De Felice, Francesca, et al.
Publicado: (2015)

Head and neck irradiation modulates pharmacokinetics of 5-fluorouracil and cisplatin
por: Hsieh, Chen-Hsi, et al.
Publicado: (2013)

A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck
por: Couteau, C, et al.
Publicado: (1999)

Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck
por: Trieu, Vanessa, et al.
Publicado: (2018)

Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients
por: Chen, Lu, et al.
Publicado: (2018)

Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China
por: Fang, Wenfeng, et al.
Publicado: (2019)

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
por: Zhang, Zhonghan, et al.
Publicado: (2019)

Multifunctional gold nanorods and docetaxel-encapsulated liposomes for combined thermo- and chemotherapy
por: Hua, Haiying, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_r6sgnbpl318m52p3602svs732p